{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:47:02Z","timestamp":1791308822410,"version":"4.3.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.revmed.2005.05.012","type":"journal-article","created":{"date-parts":[[2005,6,28]],"date-time":"2005-06-28T12:19:55Z","timestamp":1119961195000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["La caspofungine\u00a0: du m\u00e9canisme d'action aux applications th\u00e9rapeutiques"],"prefix":"10.1016","volume":"27","author":[{"given":"A.","family":"Datry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bart-Delabesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2005.05.012_bib1","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1093\/clinids\/14.Supplement_1.S43","article-title":"Opportunistic mycoses in the immunocompromised host: experienced at a cancer center and review","volume":"14","author":"Anaissie","year":"1992","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.revmed.2005.05.012_bib2","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1093\/clinids\/19.Supplement_1.S41","article-title":"Invasive aspergillosis in patients with AIDS","volume":"19","author":"Khoo","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.revmed.2005.05.012_bib3","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/infdis\/167.5.1247","article-title":"Secular trends in the epidemiology of nosocomial fungal infections in the United States","volume":"167","author":"Beck-Sagu\u00e9","year":"1993","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.revmed.2005.05.012_bib4","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/0002-9343(91)90367-7","article-title":"Nosocomial infection rates in adult and pediatric care units in the United States","volume":"91","author":"Jarvis","year":"1991","journal-title":"Am. J. Med."},{"key":"10.1016\/j.revmed.2005.05.012_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/520192","article-title":"Nosocomial bloodstreams infections in United States hospitals: a three years analysis","volume":"29","author":"Edmond","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.revmed.2005.05.012_bib6","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomised, double blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.revmed.2005.05.012_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.39.1.1","article-title":"Resistance of Candida species to fluconazole","volume":"39","author":"Rex","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.revmed.2005.05.012_bib8","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/422729","article-title":"Zygomycosis: reemergence of an old pathogen","volume":"39","author":"Kauffman","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.revmed.2005.05.012_bib9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/422723","article-title":"Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis","volume":"39","author":"Siwek","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.revmed.2005.05.012_bib10","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/ajhp\/58.13.1206","article-title":"Caspofungin acetate: an antifungal agent","volume":"58","author":"Hoang","year":"2001","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.revmed.2005.05.012_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0750-7658(01)00373-2","article-title":"Utilisation des antifongiques dans le traitement des candidoses syst\u00e9miques\u00a0: antifongigramme, point sur les r\u00e9sistances, donn\u00e9es pharmacologiques","volume":"20","author":"Datry","year":"2001","journal-title":"Ann. Fr. Anesth. Reanim."},{"key":"10.1016\/j.revmed.2005.05.012_bib12","first-page":"165","article-title":"Caspofungin. L743, 872, MK-0991, MK-991","volume":"1","year":"1999","journal-title":"Drugs R D."},{"key":"10.1016\/j.revmed.2005.05.012_bib13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/40.5.611","article-title":"Echinocandins and pneumocandins: a new antifungal class with a novel mode of action","volume":"40","author":"Denning","year":"1997","journal-title":"J. Microb. Chemother."},{"key":"10.1016\/j.revmed.2005.05.012_bib14","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.41.11.2326","article-title":"In vitro preclinical evaluation of studies with the echinocandin antifungal MK-0991 (L743, 872)","volume":"41","author":"Bartizal","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.revmed.2005.05.012_bib15","series-title":"In vitro susceptibility of clinical trial isolates of Aspergillus spp. to the glucan synthesis inhibitor caspofungin acetate (CancidasTM, MK 0991). 40th ICAAC; Toronto","author":"Flattery","year":"2000"},{"key":"10.1016\/j.revmed.2005.05.012_bib16","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.36.10.2950-2956.1998","article-title":"Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts","volume":"36","author":"Espinel-Ingroff","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.revmed.2005.05.012_bib17","series-title":"In vitro synergy studies with caspofungin and amphotericin B against Aspergillus and Fusarium. 40th ICAAC; Toronto","author":"Arikan","year":"2000"},{"key":"10.1016\/j.revmed.2005.05.012_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/02681219780001291","article-title":"In vitro growth-inhibitory activity of pneumocandins L733, 560 and L743, 872 against putatively amphotericin B and fluconazole-resistant Candida isolates: influence of assay conditions","volume":"35","author":"Nelson","year":"1997","journal-title":"J. Med. Vet. Mycol."},{"key":"10.1016\/j.revmed.2005.05.012_bib19","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.44.9.2310-2318.2000","article-title":"Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice","volume":"44","author":"Abruzzo","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.revmed.2005.05.012_bib20","series-title":"Low doses of the pneumocandin L743,872 are effective for prevention and treatment in an animal model of pulmonary aspergillosis. 36th ICAAC; News Orleans","author":"Bernard","year":"1996"},{"key":"10.1016\/j.revmed.2005.05.012_bib21","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1128\/AAC.41.11.2333","article-title":"Evaluation of the echinocandin antifungal MK-0991 (L-743, 872): efficacies of mouses models of disseminated aspergillosis, candidiasis and cryptococcosis","volume":"41","author":"Abruzzo","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.revmed.2005.05.012_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1128\/AAC.42.1.151","article-title":"Treatment of histoplasmosis with MK 0991 (L-743, 872)","volume":"42","author":"Graybill","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.revmed.2005.05.012_bib23","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1128\/AAC.42.8.1985","article-title":"Efficacy of MK0991 (L743,872), a semisynthetic pneumocandin in murin models of Pneumocystis carinii","volume":"42","author":"Powles","year":"1998","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.revmed.2005.05.012_bib24","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.49.2.830-832.2005","article-title":"Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice","volume":"49","author":"Spellberg","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.revmed.2005.05.012_bib25","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.46.3.739-745.2002","article-title":"Single and multiple dose pharmacokinetics of Caspofungin in healthy men","volume":"46","author":"Stone","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.revmed.2005.05.012_bib26","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1128\/AAC.41.11.2339","article-title":"Preliminary animal pharmacokinetics of the parenteral antifungal agent MK 0991 (L-743,872)","volume":"41","author":"Hajdu","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.revmed.2005.05.012_bib27","unstructured":"Merck and Co Cancidas (caspofungin acetate) prescribing information, Merck & Co. Available from URL: http\u00a0:\/\/www.merck.com (Accessed 2001 Mar 16)."},{"key":"10.1016\/j.revmed.2005.05.012_bib28","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0090-9556(24)15072-6","article-title":"Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine","volume":"28","author":"Balani","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.revmed.2005.05.012_bib29","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2165\/00003495-200161080-00007","article-title":"Caspofungin","volume":"61","author":"Keating","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.revmed.2005.05.012_bib30","series-title":"Pharmacokinetics of caspofungin in pediatric patients. 42nd ICAAC; San Diego","author":"Walsh","year":"2002"},{"key":"10.1016\/j.revmed.2005.05.012_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1198-743X.2004.00823.x","article-title":"Caspofungin- a new therapeutic option for oropharyngeal candidiasis","volume":"10","author":"Garbino","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.revmed.2005.05.012_bib32","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1086\/323401","article-title":"A randomized double-blind study of caspofungin versus amphotericinB for the treatment of esophageal candidiasis","volume":"33","author":"Villanueva","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.revmed.2005.05.012_bib33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.46.2.451-457.2002","article-title":"Randomized, double blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis","volume":"46","author":"Arathoon","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.revmed.2005.05.012_bib34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01191-9","article-title":"A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis","volume":"113","author":"Villanueva","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.revmed.2005.05.012_bib35","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2005.05.012_bib36","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis for patients refractory or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.revmed.2005.05.012_bib37","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2005.05.012_bib38","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/AAC.48.3.970-978.2004","article-title":"In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus","volume":"48","author":"Dannaoui","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.revmed.2005.05.012_bib39","series-title":"Multicenter noncomparative study of caspofungin combined with other antifungals in adults with invasive aspergillosis refractory or intolerant to standard regimens. 44th ICAAC; Washington","author":"Maertens","year":"2004"},{"key":"10.1016\/j.revmed.2005.05.012_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1034\/j.1399-3062.2002.01004.x","article-title":"Safety and tolerability of acetate (CA) in the treatment of fungal infections","volume":"4","author":"Sable","year":"2002","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.revmed.2005.05.012_bib41","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1592\/phco.24.14.1408.43148","article-title":"Caspofungin: a potentiel cause of reversible thrombocytopenia","volume":"24","author":"Lynch","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.revmed.2005.05.012_bib42","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1128\/AAC.48.9.3407-3411.2004","article-title":"Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations","volume":"48","author":"Stevens","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.revmed.2005.05.012_bib43","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1399-3062.2004.00065.x","article-title":"Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A","volume":"6","author":"Maar","year":"2004","journal-title":"Transpl. Infect. Dis."}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866305002675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866305002675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:14:59Z","timestamp":1759335299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866305002675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0248866305002675"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2005.05.012","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La caspofungine\u00a0: du m\u00e9canisme d'action aux applications th\u00e9rapeutiques","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2005.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}